Stockreport

Genmab Buys Ovarian Cancer Drug Developer for $1.8 Billion [BNN Bloomberg (Canada)]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF Genmab will pay cash in the transaction, which has been approved by both companies' boards, the Copenhagen-based pharmaceutical firm said in a statement on Wednesday. [Read more]